ES2210832T3 - Secuencias de aminoacidos para uso terapeutico y profilactico contra enfermedades debidas a las toxinas de clostridium difficile. - Google Patents

Secuencias de aminoacidos para uso terapeutico y profilactico contra enfermedades debidas a las toxinas de clostridium difficile.

Info

Publication number
ES2210832T3
ES2210832T3 ES98951374T ES98951374T ES2210832T3 ES 2210832 T3 ES2210832 T3 ES 2210832T3 ES 98951374 T ES98951374 T ES 98951374T ES 98951374 T ES98951374 T ES 98951374T ES 2210832 T3 ES2210832 T3 ES 2210832T3
Authority
ES
Spain
Prior art keywords
baselineskip
seq
sequence
antibody
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98951374T
Other languages
English (en)
Spanish (es)
Inventor
Christoph Von Eichel-Streiber
Michael Moos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2210832T3 publication Critical patent/ES2210832T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/13—Immunoglobulins specific features characterized by their source of isolation or production isolated from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES98951374T 1997-09-10 1998-09-10 Secuencias de aminoacidos para uso terapeutico y profilactico contra enfermedades debidas a las toxinas de clostridium difficile. Expired - Lifetime ES2210832T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19739685 1997-09-10
DE19739685A DE19739685A1 (de) 1997-09-10 1997-09-10 Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile

Publications (1)

Publication Number Publication Date
ES2210832T3 true ES2210832T3 (es) 2004-07-01

Family

ID=7841840

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98951374T Expired - Lifetime ES2210832T3 (es) 1997-09-10 1998-09-10 Secuencias de aminoacidos para uso terapeutico y profilactico contra enfermedades debidas a las toxinas de clostridium difficile.

Country Status (11)

Country Link
US (2) US6667035B1 (https=)
EP (1) EP0994904B1 (https=)
JP (1) JP4318398B2 (https=)
CN (1) CN1273588A (https=)
AT (1) ATE254139T1 (https=)
AU (1) AU9742698A (https=)
BR (1) BR9815367A (https=)
CA (1) CA2303202C (https=)
DE (2) DE19739685A1 (https=)
ES (1) ES2210832T3 (https=)
WO (1) WO1999012971A2 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19739685A1 (de) * 1997-09-10 1999-03-11 Eichel Streiber Christoph Von Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile
WO2002062379A2 (en) * 2001-02-09 2002-08-15 The Provost, Fellows And Scholars Of The College Of The Holy And Unidivided Trinity Of Queen Elizabeth Clostridium difficile vaccine
GB0130267D0 (en) * 2001-12-19 2002-02-06 Neutec Pharma Plc Focussed antibody technology
GB0205206D0 (en) * 2002-03-06 2002-04-17 Oxoid Ltd Synthetic peptides
GB0309126D0 (en) * 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies
LT2857418T (lt) 2004-02-06 2017-09-25 University Of Massachusetts Antikūnai prieš clostridium difficile toksinus ir jų panaudojimas
ATE385423T1 (de) * 2004-06-16 2008-02-15 Straumann Holding Ag Abdeckmembran
GB0414886D0 (en) 2004-07-02 2004-08-04 Neutec Pharma Plc Treatment of bacterial infections
US20090087478A1 (en) * 2004-12-27 2009-04-02 Progenics Pharmaceuticals (Nevada), Inc. Orally Deliverable and Anti-Toxin Antibodies and Methods for Making and Using Them
CA2618796C (en) 2005-08-11 2018-01-02 Arpi Matossian-Rogers Peptides for treatment and diagnosis of autoimmune disease
AU2012241141B2 (en) * 2005-08-11 2015-08-20 Arpi Matossian-Rogers TCR-V-beta related peptides for treatment and diagnosis of autoimmune disease
CA2680741A1 (en) 2007-03-22 2009-01-15 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US20090280134A1 (en) * 2008-05-09 2009-11-12 Recopharma Ab Compositions and methods for inhibiting toxin a from clostridium difficile
DE102008029688B4 (de) * 2008-06-24 2016-06-23 Biodics Gmbh Verfahren zum Nachweis und zur Identifikation eines varianten C. difficile Stammes in einer Probe
WO2010014854A2 (en) 2008-07-31 2010-02-04 The Regents Of The University Of California Antibodies that neutralize botulinum neurotoxins
US8889363B2 (en) 2009-07-27 2014-11-18 Biodics Method for the detection and identification of a variant C. difficile strain in a sample
CA2768528C (en) * 2009-07-27 2017-05-23 Christoph Von Eichel-Streiber Method for detecting and identifying a variant c. difficile strain in a sample
WO2011060076A1 (en) * 2009-11-10 2011-05-19 Amgen Inc. Anti-c-mpl antibodies
US9243057B2 (en) 2010-08-31 2016-01-26 The Regents Of The University Of California Antibodies for botulinum neurotoxins
WO2012118693A1 (en) * 2011-02-28 2012-09-07 Northshore University Healthsystem Methods of diagnosing clostridium difficile infection
AR086199A1 (es) 2011-04-22 2013-11-27 Wyeth Llc Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos
US9505847B2 (en) * 2011-08-22 2016-11-29 Cnj Holdings Inc Clostridium difficile antibodies
US10364298B2 (en) 2011-11-18 2019-07-30 National Research Council Of Canada Clostridium difficile lipoteichoic acid and uses thereof
HK1200463A1 (en) * 2012-03-02 2015-08-07 瑞泽恩制药公司 Human antibodies to clostridium difficile toxins
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
CN109776676A (zh) * 2012-11-28 2019-05-21 Cnj控股公司 针对艰难梭菌的抗体
EP4079760A3 (en) 2013-03-15 2023-01-25 Sanofi Pasteur Inc. Antibodies against clostridium difficile toxins and methods of using the same
EP4168032A2 (en) 2020-06-19 2023-04-26 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879218A (en) 1982-09-13 1989-11-07 Virginia Tech Intellectual Properties, Inc. Antibody for C.difficile
DE3471661D1 (en) 1984-03-02 1988-07-07 Tracy Dale Wilkins Toxins and antibodies of c. difficile
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4863852A (en) 1985-07-03 1989-09-05 Virginia Tech Intellectual Properties, Inc. Method of detecting, isolating and purifying clostridium difficile toxin A and its receptors
US5071759A (en) * 1986-05-30 1991-12-10 The United States Of America As Represented By The Secretary Of The Army Hybridoma cell lines and monoclonal antibodies to clostridum difficile toxins A and B
US5580774A (en) * 1989-07-31 1996-12-03 Eli Lilly And Company Chimeric antibodies directed against a human glycoprotein antigen
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
US5098826A (en) 1990-03-09 1992-03-24 Virginia Tech Intellectual Properties, Inc. Detection, isolation and purification of Clostridium difficile toxin A with toxin receptors
US5231003A (en) * 1990-05-11 1993-07-27 Cambridge Bioscience Corporation Monoclonal antibodies specific for toxin b of clostridium difficile
US5858725A (en) 1990-10-10 1999-01-12 Glaxo Wellcome Inc. Preparation of chimaeric antibodies using the recombinant PCR strategy
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
GB9317423D0 (en) * 1993-08-21 1993-10-06 Imp Cancer Res Tech Monoclonal antibodies
CA2203504A1 (en) * 1994-10-24 1996-05-02 James A. Williams Vaccine and antitoxin for treatment and prevention of c. difficile disease
DE19739685A1 (de) * 1997-09-10 1999-03-11 Eichel Streiber Christoph Von Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile

Also Published As

Publication number Publication date
DE19739685A1 (de) 1999-03-11
AU9742698A (en) 1999-03-29
JP2001515920A (ja) 2001-09-25
BR9815367A (pt) 2001-11-06
EP0994904B1 (de) 2003-11-12
CA2303202A1 (en) 1999-03-18
EP0994904A2 (de) 2000-04-26
ATE254139T1 (de) 2003-11-15
JP4318398B2 (ja) 2009-08-19
WO1999012971A3 (de) 1999-07-22
US7151159B2 (en) 2006-12-19
CA2303202C (en) 2010-04-27
US6667035B1 (en) 2003-12-23
DE59810172D1 (de) 2003-12-18
CN1273588A (zh) 2000-11-15
WO1999012971A2 (de) 1999-03-18
US20040137601A1 (en) 2004-07-15

Similar Documents

Publication Publication Date Title
ES2210832T3 (es) Secuencias de aminoacidos para uso terapeutico y profilactico contra enfermedades debidas a las toxinas de clostridium difficile.
RU2757813C2 (ru) Антитело против lag-3, его антигенсвязывающий фрагмент и их фармацевтическое применение
FI115462B (fi) Menetelmä immunoglobuliinin valmistamiseksi
AU2018243123B2 (en) B7-H3 antibody, antigen-binding fragment thereof and medical use thereof
EP3689909A1 (en) Tigit antibody, antigen-binding fragment thereof, and medical use thereof
ES2052027T5 (es) Clonacion de secuencias de dominio variable de inmunoglobulina.
EP0937140B1 (en) Antibody molecules which interact specifically with the active site or cleft of a target molecule
JP4954104B2 (ja) Ｉｌ−５介在障害を治療および診断するための改良方法
HK1247214B (zh) 一种pdl-1抗体、其药物组合物及其用途
JP2012515746A (ja) 抗ｃｄ１６０モノクローナル抗体及びその使用
WO2019091449A1 (zh) Cd96抗体、其抗原结合片段及医药用途
CN112513088B (zh) 抗ox40抗体、其抗原结合片段及其医药用途
TW526206B (en) Reshaped human antibody to human medulloblastoma cells
CN102906111A (zh) 特异性结合乙型肝炎病毒表面抗原的人抗体
CN101580546B (zh) 人源抗人干扰素α抗体及其应用
KR101613347B1 (ko) 비브리오 패혈증균 알티엑스에이-1 단백질에 특이적으로 결합하는 단일클론항체 및 이의 용도
EP1079856B1 (en) Humanized antibodies that recognize verotoxin ii and cell line producing same
CN100441689C (zh) 抗ehec o157志贺样毒素ⅱa亚单位单克隆抗体5f3轻、重链可变区基因及应用
KR100506118B1 (ko) 수막염균증 백신 조성물
KR100509993B1 (ko) Il-5 매개된 질환의 치료에 유용한 재조합 il-5 길항제
MXPA00002491A (en) Amino acid sequences for therapeutical and prophylactic applications to diseases due to clostridium difficile
KR20040084875A (ko) Ｂ형 간염 바이러스의 표면 항원에 대한 인간항체의가변영역을 삽입할 수 있는 항체발현 플라스미드
WO2022063100A1 (zh) 抗tigit抗体及双抗体和它们的应用
KR101553845B1 (ko) 비브리오 패혈증균 알티엑스에이-1 단백질에 특이적으로 결합하는 단일클론항체 및 이의 용도
CN121824774A (zh) 一种治疗李斯特菌病的双特异性抗体及其药物组合物